QIAGEN logo

Unlock the full story: Determining the feasibility and sensitivity of detecting tumor-derived cfDNA from urine in TNBC patients

Please fill out the form to read the full story of how Leipzig University compared both the qualitative and quantitative aspects of somatic variant detection from plasma and urine in treatment-naïve TNBC patients leveraging cutting-edge Sample to Insight tools from QIAGEN.

Thank you for submitting the form.
Dummy field DO NOT USE/ DELETE/ MODIFY Needs to be hidden in CSS on LP
Required only for USA & Canada














I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further contests, special offers and product information.

* Mandatory fields

Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. All information you provide in this site will be governed by our Privacy Policy.